Editorial Commentary: Considering Clinical Application of Bone Marrow Aspirate Concentrate for Restoration of Cartilage Defects in the Knee? Is It a Kind of Stem Cell Therapy?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 31159970.
- Also identified by DOI 10.1016/j.arthro.2019.03.008.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The role of bone marrow aspirate concentrate (BMAC) is still inconclusive for restoration of chondral defects in lesions of the knee. More investigation is needed; thus, clinical application of BMAC for chondral defects should be considered cautiously. Correct nomenclature of the entity of cells used in various stem cell therapies for the treatment of cartilage lesions is critical to properly assess the efficacy and safety of various stem cell therapies. Constant effort is needed to prove the therapeutic potential of various novel therapeutic options such as BMAC or stem cell therapy under correct terminology for cartilage restoration before routine clinical application.
Medical subject headings
- Cartilage Diseases
- Mesenchymal Stem Cell Transplantation
Anatomy
- knee